Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
(Stockholm October 19, 2021) Inhalation Sciences AB (ISAB) has received a new order worth 202 KEUR (2.025 MSEK) from a major inhaled pharma company in China specializing in asthma and COPD treatments for the global market. The order is for ISAB's PreciseInhale® aerosol generating platform and its in vitro lung simulation module DissolvIt®.
The comprehensive new order covers installation, tech transfer, training and service and support for ISAB's entire PreciseInhale® platform - plus its in vitro lung simulation module DissolvIt®. DissolvIt® is widely recognized as being a leading solution in the field of high-precision, predictive in vitro in vivo correlation (IVIC) data, reducing risk and identifying strong drug candidates very early in the development process - a major competitive advantage for inhaled drug developers.
ISAB CEO Manoush Masarrat: "China is one of the largest, most innovative and most high-potential markets in the world for inhaled therapies. We are very proud that our technology has been chosen by one of this market's major players. This is a hugely important sale for ISAB and we look forward to continuing our collaboration with this new customer in this vital and exciting market."